---
title: 'Research Associate I/II, Preclinical Research (Contract) at Lexeo Therapeutics'
canonical: 'https://feeny.ai/job/research-associate-i-ii-preclinical-research-contract-lexeo-therapeutics-new-5cprbry5kqq2'
type: 'job'
last_seen: '2026-10-19'
---

# Research Associate I/II, Preclinical Research (Contract) at Lexeo Therapeutics

- **Company:** Lexeo Therapeutics
- **Location:** New York, NY
- **Employment:** contract
- **Work type:** onsite
- **Posted:** 2026-10-15
- **Last confirmed live:** 2026-10-19
- **Apply:** https://jobs.lever.co/lexeotx/bf96f32b-4b67-44be-9d06-bf25f721f9a4

## Job description

## Role Summary

The Research Associate I/II will support Lexeo’s human induced pluripotent stem cell–derived cardiomyocyte (iPSC-CM) platform, a core in vitro system used to evaluate target engagement, mechanism of action, and potency across discovery and preclinical programs. This hands-on laboratory role will execute established cellular and molecular assays, contribute to assay development, and generate high-quality data. The position reports to the Head of Cardiac Research and receives day-to-day scientific direction from the Preclinical Scientist leading the platform. This is an exciting opportunity to join a cutting-edge drug discovery team advancing new therapies for patients with genetic heart disease while gaining valuable experiences for a future career in biotech and medicine

Primary Responsibilities

- Generate and validate cellular knockdown and overexpression models
- Culture and maintain human iPSC-derived cardiomyocytes and other mammalian cell lines using aseptic technique
- Perform ddPCR, qPCR, conventional PCR, gel electrophoresis, Western blotting, and ELISA to support mechanism-of-action and target-validation studies
- Maintain complete and accurate laboratory records and contribute to the development and revision of assay SOPs
- Analyze experimental data and prepare concise summaries for Preclinical team

Required Skills and Qualifications

- Bachelor’s degree in cell biology, molecular biology, pharmacology, or a related field with 1-3 years of industry and/or academic lab experience
- Hands-on experience culturing iPSC and differentiation protocols for cardiomyocytes/neurons
- Hands-on experience with cellular transfection methods
- Experience with several of the following methods: ddPCR, qPCR, semi-quantitative PCR, Western blotting, ELISA, flow cytometry, and fluorescence microscopy
- Strong laboratory skills, rigorous record-keeping, attention to detail, and the ability to work effectively in a fast-paced environment
- Ability to work onsite 5 days/week at our New York City HQ

## Preferred Skills and Qualifications

- Prior experience in an in vitro pharmacology group within the biotechnology or pharmaceutical industry
- Experience with high-throughput screening platforms, automation and workflows
- Experience with the Jess automated Western blotting platform
- Experience with TR-FRET, NanoBiT, FLIPR, or MEA assays
- Familiarity with engineered heart tissue models and cardiac biology
- Familiarity with AI-native, agentic lab-in-the-loop workflows connecting experimental design, automated execution, real-time data analysis, and iterative decision-making
- Demonstrated ability to generate, document, and communicate high-quality experimental results; publications or patents are a plus

## About LEXEO

Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.

## About Lexeo Therapeutics

## Company Overview
- **One-liner**: Lexeo Therapeutics is a clinical-stage genetic medicine company pioneering gene therapies to treat the root causes of inherited cardiovascular diseases and APOE4-associated Alzheimer’s disease.
- **Entity Type**: Public (NYSE: LXEO) – IPO in 2023
- **Headquarters**: New York, New York, United States (345 Park Avenue South, Floor 6)
- **Founded**: 2018
- **Founders**: Ronald Crystal, MD (Founder & Chief Scientific Adviser)

## Core Business
- **Primary industry/industries**: Biotechnology / Genetic Medicine / Gene Therapy
- **Target customers**: B2B (healthcare providers, clinical research institutions, patients via healthcare systems) – focus on larger-rare and prevalent cardiovascular indications with high unmet need.
- **Mission or purpose statement**: “Reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated” (from 10-K) – also “going beyond treating the symptoms of genetic disease by trying to stop its progress at its underlying cause” (from careers page).

## Products & Services
- **LX2006**: Gene therapy candidate for cardiomyopathy associated with Friedreich’s Ataxia (FA). Currently in Phase 1/2 SUNRISE-FA trial; positive interim data reported in 2025/2026. Plans to initiate a registrational study (SUNRISE-FA 2) in H1 2026.
- **LX2020**: Gene therapy candidate for arrhythmogenic cardiomyopathy (ACM) caused by PKP2 mutations. In Phase 1/2 HEROIC-PKP2 trial; positive interim data announced January 2026.
- **Preclinical pipeline**: Additional programs targeting hypertrophic cardiomyopathy, APOE4-associated Alzheimer’s disease, and other genetically defined conditions.

## Market Standing
- **Valuation/Market Cap**: $329.6 million (as of recent data from LinkedIn, 2026)
- **Key Metric**: Annual revenue of $654K (pre-commercial, clinical-stage); total funding not directly disclosed but backed by IPO and institutional investors.
- **Notable Investors/Partners**: Partnerships with Weill Cornell Medicine and University of California San Diego; institutional investors include those common in biotech IPOs (specific names not listed in provided sources).
- **Growth Signals**: 
  - Headcount grew 18.5% YoY to 81 employees (LinkedIn).
  - Positive interim clinical data for both lead programs.
  - FDA feedback expected Q2 2026 for registrational trial design.
  - Expanded pipeline into AI/Data Science for drug discovery (new Sr. Director role posted).

## Competitive Advantages
- **AAVrh10 vector technology**: High transduction efficiency in myocardial cells, lower toxicity potential, and low pre-existing immunity compared to other AAV serotypes.
- **Focus on larger-rare cardiovascular diseases**: Targeting conditions with high unmet need and no approved treatments, enabling a stepwise, capital-efficient development approach.
- **Strong academic partnerships**: Groundbreaking research from Weill Cornell and UCSD provides foundational science and credibility.
- **Full ownership**: Retains exclusive worldwide development and commercialization rights to all product candidates.

## Strategic Focus
- **Late-stage clinical advancement**: Pushing LX2006 and LX2020 toward registrational trials and potential BLA submission.
- **AI and data science integration**: Hiring a Senior Director of AI and Data Science to accelerate decision-making across discovery, development, and operations.
- **Expanding pipeline**: Leveraging early proof-of-concept data to address larger-rare and prevalent indications beyond current lead programs.
- **Manufacturing and CMC**: Scaling up AAV manufacturing processes using Sf9/baculovirus and HEK-based systems.

## Why Work Here
- **Culture**: “Passion to change the arc of medicine” – a mission-driven environment focused on transformative gene therapies.
- **Work model**: Hybrid – 2 days/week in the New York City office, 3 days remote (from careers page).
- **Compensation & benefits**:
  - Competitive salaries (e.g., Director/Sr. Director Clinical Development: $247,500 – $382,000/year)
  - Health, dental, vision, mental health benefits
  - 401(K) with company match, performance bonus, company equity
  - Unlimited PTO, paid holidays, paid parental leave
  - Commuter benefits, tech stipend, stocked kitchen, in-office lunch stipend
  - Life and disability insurance
- **Team**: Led by pioneers in gene therapy and rare disease drug development; small but growing company (81 employees) offering high impact and cross-functional ownership.
- **EEO**: Committed to an exciting, diverse, and enriching work environment.

## Sources
1. [sec.gov](https://www.sec.gov/Archives/edgar/data/1907108/000119312526193939/ars_10-k_2025.pdf) – Form 10-K for FY2025 (filed March 2026)
2. [linkedin.com](https://linkedin.com/company/lexeo-therapeutics) – LinkedIn company page (employees, revenue, market cap)
3. [lexeotx.com](https://www.lexeotx.com/careers/) – Careers page (benefits, culture, hybrid policy, job postings)
4. [jobs.lever.co](https://jobs.lever.co/lexeotx) – Lever job board (open positions)
5. [lexeotx.com](https://www.lexeotx.com/team/) – Leadership team page (founder, executives)

## Other roles at Lexeo Therapeutics

- [Scientist II, Cellular Neuroscience and Translational Pharmacology](https://feeny.ai/job/scientist-ii-cellular-neuroscience-and-translational-pharmacology-lexeo-b4597dp1w5gp) — New York, NY
- [Manager/Senior Manager, CMC Quality Control](https://feeny.ai/job/manager-senior-manager-cmc-quality-control-lexeo-therapeutics-new-york-ak1xnmwz3p3y) — New York, NY
- [Director/Senior Director, Clinical Development](https://feeny.ai/job/director-senior-director-clinical-development-lexeo-therapeutics-new-york-vkywdkr3hqn8) — New York, NY